BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Burstein HJ, Somerfield MR, Barton DL, Dorris A, Fallowfield LJ, Jain D, Johnston SRD, Korde LA, Litton JK, Macrae ER, Peterson LL, Vikas P, Yung RL, Rugo HS. Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update. J Clin Oncol 2021;:JCO2101392. [PMID: 34324367 DOI: 10.1200/JCO.21.01392] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
Number Citing Articles
1 Miglietta F, Bottosso M, Griguolo G, Dieci M, Guarneri V. Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival. ESMO Open 2022;7:100409. [DOI: 10.1016/j.esmoop.2022.100409] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
2 Bui TBV, Burgering BMT, Goga A, Rugo HS, van 't Veer LJ. Biomarkers for Cyclin-Dependent Kinase 4/6 Inhibitors in the Treatment of Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced/Metastatic Breast Cancer: Translation to Clinical Practice. JCO Precis Oncol 2022;6:e2100473. [PMID: 35666959 DOI: 10.1200/PO.21.00473] [Reference Citation Analysis]
3 Botty van den Bruele A, Ferraro E, Sevilimedu V, Hogan MP, Javed-Tayyab S, Le T, Fornier MN, Morrow M, Sacchini V. Does preoperative MRI accurately stratify early-stage HER2 + breast cancer patients to upfront surgery vs neoadjuvant chemotherapy? Breast Cancer Res Treat 2021;189:307-15. [PMID: 34263366 DOI: 10.1007/s10549-021-06331-3] [Reference Citation Analysis]
4 Cho YA, Ko SY, Suh YJ, Kim S, Park JH, Park H, Seo J, Choi HG, Kang HS, Lim H, Park HY, Kwon MJ. PIK3CA Mutation as Potential Poor Prognostic Marker in Asian Female Breast Cancer Patients Who Received Adjuvant Chemotherapy. Current Oncology 2022;29:2895-908. [DOI: 10.3390/curroncol29050236] [Reference Citation Analysis]
5 Makarem M, García-Pardo M, Leighl NB. Plasma-Based Genotyping in Advanced Solid Tumors: A Comprehensive Review. Cancers (Basel) 2021;13:5299. [PMID: 34771462 DOI: 10.3390/cancers13215299] [Reference Citation Analysis]
6 . Systemtherapie des HR-positiven, HER2-negativen metastasierten Mammakarzinoms. Geburtshilfe Frauenheilkd 2022;82:257-8. [DOI: 10.1055/a-1684-3424] [Reference Citation Analysis]
7 Chan HT, Chin YM, Low S. Circulating Tumor DNA-Based Genomic Profiling Assays in Adult Solid Tumors for Precision Oncology: Recent Advancements and Future Challenges. Cancers 2022;14:3275. [DOI: 10.3390/cancers14133275] [Reference Citation Analysis]
8 Nabieva N, Fasching PA. Endocrine Treatment for Breast Cancer Patients Revisited-History, Standard of Care, and Possibilities of Improvement. Cancers (Basel) 2021;13:5643. [PMID: 34830800 DOI: 10.3390/cancers13225643] [Reference Citation Analysis]
9 Yu J, Li NL. Loss of human epidermal receptor-2 in human epidermal receptor-2+ breast cancer after neoadjuvant treatment: A case report. World J Clin Cases 2022; 10(17): 5923-5928 [DOI: 10.12998/wjcc.v10.i17.5923] [Reference Citation Analysis]
10 Meng Y, Ying Y, Zhang M, Zhang S, Yao Y, Li D. A comprehensive bioinformatic analysis of RanBP9 expression and its relation to prognosis in human breast cancer. Epigenomics 2022;14:27-42. [PMID: 34875851 DOI: 10.2217/epi-2021-0464] [Reference Citation Analysis]
11 Bidard FC, Kaklamani VG, Neven P, Streich G, Montero AJ, Forget F, Mouret-Reynier MA, Sohn JH, Taylor D, Harnden KK, Khong H, Kocsis J, Dalenc F, Dillon PM, Babu S, Waters S, Deleu I, García Sáenz JA, Bria E, Cazzaniga M, Lu J, Aftimos P, Cortés J, Liu S, Tonini G, Laurent D, Habboubi N, Conlan MG, Bardia A. Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial. J Clin Oncol 2022;:JCO2200338. [PMID: 35584336 DOI: 10.1200/JCO.22.00338] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Henry NL, Somerfield MR, Dayao Z, Elias A, Kalinsky K, McShane LM, Moy B, Park BH, Shanahan KM, Sharma P, Shatsky R, Stringer-Reasor E, Telli M, Turner NC, DeMichele A. Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update. J Clin Oncol 2022;:JCO2201063. [PMID: 35759724 DOI: 10.1200/JCO.22.01063] [Reference Citation Analysis]
13 Pfeiler G, Demichele A, Dueck AC, Fesl C, Gnant M, Mayer EL. Safety of adjuvant CDK4/6 inhibitors during the COVID-19 pandemic. The Lancet Oncology 2022;23:195-7. [DOI: 10.1016/s1470-2045(21)00708-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]